Damora Therapeutics Income Statement (2019-2026) | DMRA

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating items
Research & Development (Quarter)
9.75M10.12M13.23M13.71M10.49M10.77M10.36M8.09M2.55M2.77M2.46M1.83M1.09M1.01M0.68M1.47M1.42M23.32M23.78M25.54M
Selling, General & Administrative (Quarter)
3.19M3.35M3.70M3.41M3.13M2.75M3.13M3.07M3.30M3.18M3.28M2.77M2.75M1.70M1.92M1.96M1.74M4.07M7.03M9.45M
Other Operating Expenses (Quarter)
2.73M0.72M0.97M4.39M174.31M
Operating Expenses (Quarter)
12.94M13.47M16.94M17.12M13.62M13.53M13.49M11.16M8.58M6.67M5.74M5.58M3.84M7.10M2.60M3.42M3.16M201.70M30.81M34.99M
Operating Income (Quarter)
-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-11.16M-8.58M-6.67M-5.74M-5.58M-3.84M-7.10M-2.60M-3.42M-3.16M-201.70M-30.81M-34.99M
EBIT (Quarter)
-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-11.16M-8.58M-6.67M-5.74M-5.58M-3.84M-7.10M-2.60M-3.42M-3.16M-201.70M-30.81M-34.99M
Non-operating items
Non Operating Investment Income (Quarter)
0.03M-0.05M-0.20M-0.07M-0.08M-0.19M0.09M0.03M0.06M0.06M0.03M0.00M
Other Non Operating Income (Quarter)
0.21M0.03M-0.06M0.15M-0.33M-0.83M0.06M-0.03M-0.03M-0.21M0.01M0.07M-0.18M0.12M-0.01M-0.06M-0.02M0.00M0.02M
Non Operating Income (Quarter)
0.24M0.06M0.00M0.23M-0.11M-0.54M0.50M0.41M0.45M0.20M0.26M0.28M-0.04M0.35M0.07M-0.01M0.02M1.00M3.07M4.08M
Net income details
EBT (Quarter)
-15.00M-13.58M-17.28M-17.24M-13.76M-13.68M-14.92M-10.74M-8.14M1.67M-5.48M-5.30M-3.88M-6.75M-2.53M-3.43M-3.13M-196.83M-27.74M-30.92M
Tax Provisions (Quarter)
0.04M0.01M-0.01M0.00M0.00M0.04M0.04M0.30M
Profit After Tax (Quarter)
-13.03M-14.40M-0.38M-16.89M-14.16M49.24M-12.99M-10.75M-7.95M-5.85M-5.53M-5.47M-3.42M-6.74M-2.33M0.51M0.01M9.08M-27.78M-31.20M
Income from Continuing Operations (Quarter)
-15.00M-13.58M-17.28M-17.24M-13.76M-13.68M-14.92M-10.74M-8.14M1.67M-5.48M-5.34M-3.88M-6.74M-2.53M-3.44M-3.13M-196.88M-27.78M-31.22M
Consolidated Net Income (Quarter)
-15.00M-13.58M-17.28M-17.24M-13.76M-13.68M-14.92M-10.74M-8.14M1.67M-5.48M-5.34M-3.88M-6.74M-2.53M-3.44M-3.13M-196.88M-27.78M-31.22M
Income towards Parent Company (Quarter)
-15.00M-13.58M-17.28M-17.24M-13.76M-13.68M-14.92M-10.74M-8.14M1.67M-5.48M-5.34M-3.88M-6.74M-2.53M-3.44M-3.13M-196.88M-27.78M-31.22M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-12.70M-13.58M-17.28M-17.24M-13.76M-13.68M-14.92M-10.74M-8.14M1.67M-5.48M-5.34M-3.88M-6.74M-2.53M-3.44M-3.13M-196.88M-27.78M-31.22M
Additional items
EPS (Basic) (Quarter)
-0.50-0.54-0.68-0.68-0.54-0.54-0.58-0.41-0.300.06-0.20-0.20-3.39-5.83-1.92-2.60-2.36-144.44-0.81-0.51
EPS (Diluted) (Quarter)
-0.50-0.54-0.68-0.68-0.54-0.54-0.58-0.41-0.300.06-0.20-0.20-3.39-5.83-1.92-2.60-2.36-144.44-0.81-0.51
Shares Outstanding (Quarter)
25.26M25.26M25.26M25.27M25.49M25.41M25.67M26.38M27.10M26.57M27.11M27.12M1.14M1.16M1.32M1.32M1.33M1.36M34.30M61.12M
Shares Outstanding (Diluted) (Quarter)
25.26M25.26M25.26M25.27M25.49M25.41M25.67M26.38M27.10M26.57M27.11M27.12M1.14M1.16M1.32M1.32M1.33M1.36M34.30M61.12M
Shares Outstanding (Entity) (Quarter)
25.26M25.26M25.26M25.34M25.58M25.65M25.67M27.02M27.11M27.11M27.11M27.12M1.25M1.32M1.32M1.32M1.33M1.60M34.30M61.74M
EBITDA (Quarter)
-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-11.16M-8.58M-6.67M-5.74M-5.58M-3.84M-7.10M-2.60M-3.42M-3.16M-201.70M-30.81M-34.99M
Interest Expenses (Quarter)
2.06M0.11M0.34M0.12M0.13M0.15M1.43M3.26M0.12M0.17M0.09M0.05M0.05M0.03M0.09M0.09M0.02M0.01M11.42M11.07M
Tax Rate (Quarter)
-0.79%-0.18%0.12%-0.08%-0.12%-0.02%-0.15%-0.97%